

Comprehensive genomic and tailored biomarker insights for optimal therapy selection in a single order

Cancer type	Cancer type-specific IHC additions
Biliary/Cholangiocarcinoma	PD-L1 (22C3), HER2 CDx, CLDN18.2
Bladder	PD-L1 (22C3), HER2
Breast	ER, PR, HER2 CDx, PD-L1 CDx* (22C3), Ki-67, AR
Cervical	PD-L1 CDx (22C3), HER2
Colorectal	HER2
Endometrial/Uterine carcinoma	PD-L1 (22C3), HER2 CDx, ER, p53, PR, PTEN
Esophageal adenocarcinoma (EAC)	PD-L1 CDx (22C3), HER2, CLDN18.2, PD-L1 CDx (28-8)
Esophageal squamous cell carcinoma (ESCC)	PD-L1 CDx (22C3), PD-L1 CDx (28-8)
Gastric/GEJ	PD-L1 CDx (22C3), HER2 CDx, CLDN18.2 CDx, PD-L1 CDx (28-8)
Head and neck squamous cell carcinoma (HNSCC)	PD-L1 CDx (22C3), HER2, HPV RNA ISH Panel
Hepatocellular carcinoma	PD-L1 (22C3), HER2
Melanoma	PD-L1 (22C3)
Non-small cell lung cancer (NSCLC)**	PD-L1 CDx (22C3), PD-L1 CDx (SP142), c-MET CDx, ALK CDx, HER2, ROS1
Ovarian/Fallopian/Peritoneal	PD-L1 CDx (22C3), FOLR1 CDx, HER2, ER, PR, HRD [†] through NGS-based scoring
Pancreatic	PD-L1 (22C3), HER2, CLDN18.2
Prostate	PTEN CDx, PD-L1 (22C3), HER2, AR
Renal/Renal Cell Carcinoma (RCC)	PD-L1 (22C3), HER2
Sarcoma/GIST	PD-L1 (22C3), HER2
Thyroid	PD-L1 (22C3), HER2
Cancer of unknown primary (CUP)	PD-L1 (22C3), HER2
Other	PD-L1 (22C3), HER2

HER2 FISH reflex will occur for resulted 2+ equivocal IHC results.

If selected with order, PanTracer LBx will be added as a reflex if tissue testing is not possible or fails.

When tissue is limited, tests will be performed in the order listed above.

* For breast cases, PD-L1 (22C3) serves as a companion diagnostic in triple-negative breast cancer (TNBC).

** PD-L1 CDx 28-8 and PD-L1 CDx SP263 are available to add to NSCLC cases by request.

[†] Our HRD assessment covers BRCA1/BRCA2 mutation status and tumor genomic instability score (GIS) - including LOH, TAI and LST.

HRD scoring is validated for primary epithelial ovarian tumors only and is not available to New York State clients.

CDx = companion diagnostic; FISH = fluorescence in situ hybridization; GEJ = gastroesophageal junction; GIST = gastrointestinal stromal tumor; HPV = human papillomavirus; HRD = homologous recombination deficiency; IHC = immunohistochemistry; ISH = in situ hybridization; NGS = next-generation sequencing

NeoGenomics, Inc. is a premier cancer diagnostics company specializing in cancer genetics testing and information services. We offer one of the most comprehensive oncology-focused testing menus across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with innovative diagnostic and predictive testing to deliver timely, actionable insights that guide personalized care decisions. Headquartered in Fort Myers, FL, NeoGenomics operates a network of CAP-accredited and CLIA-certified laboratories for full-service sample processing and analysis services throughout the US and a CAP-accredited full-service sample-processing laboratory in Cambridge, England. ©2026 NeoGenomics Laboratories, Inc. All rights reserved.